Status epilepticus in adults

Handbook of Clinical Neurology

Volumn 108, Issue , 2012, Pages 813-819

  Rosenow, Felix ^a   Knake, Susanne ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865579802     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52899-5.00029-0     Document Type: Chapter

References (99)

1. America's Working Group on Status Epilepticus (1993). Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA 270: 854-859.
2. Abend N.S., Monk H.M., Licht D.J., et al. Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures. Pediatr Crit Care Med 2009, 10(4):505-510.
3. Aiguabella M., Falip M., Villanueva V., et al. Efficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: a multicentric observational study. Seizure 2011, 20:60-64.
4. Alldredge B.K., Gelb A.M., Isaacs S.M., et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001, 345:631-637.
5. Aminoff M.J., Simon R.P. Status epilepticus. Causes, clinical features and consequences in 98 patients. Am J Med 1980, 69:657-666.
6. Berning S., Boesebeck F., van Baalen A., et al. Intravenous levetiracetam as treatment for status epilepticus. J Neurol 2009, 256:1634-1642.
7. Beyenburg S., Reuber M., Maraite N. Intravenous levetiracetam for epileptic seizure emergencies in older people. Gerontology 2008, 55:27-31.
8. Beyreuther B.K., Freitag J., Heers C., et al. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007, 13:21-42.
9. Bialer M., Johannessen S.I., Levy R.H., et al. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 2009, 83:1-43.
10. Biton V., Rosenfeld W.E., Whitesides J., et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008, 49:418-424.
11. Bleck T.P. Advances in the management of refractory status epilepticus. Crit Care Med 1993, 21:955-957.
12. Browne T.R., Kugler A.R., Eldon M.A. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 1996, 46:S3-S7.
13. Burneo J.G., Anandan J.V., Barkley G.L. A prospective study of the incidence of the purple glove syndrome. Epilepsia 2001, 42:1156-1159.
14. Chokshi R., Openshaw J., Mehta N.N., et al. Purple glove syndrome following intravenous phenytoin administration. Vasc Med 2007, 12:29-31.
15. Claassen J., Hirsch L.J., Emerson R.G., et al. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002, 43:146-153.
16. Cock H.R., Schapira A.H. A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. Q J Med 2002, 95:225-231.
17. Coeytaux A., Jallon P., Galobardes B., et al. Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology 2000, 55:693-697.
18. Commission on Classification and Terminology of the International League Against Epilepsy Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989, 30:389-399.
19. Del Gado-Escueta A.V., Wasterlain C., Treiman D.M., et al. Current concepts in neurology: management of status epilepticus. N Engl J Med 1982, 306:1337-1340.
20. DeLorenzo R.J., Pellock J.M., Towne A.R., et al. Epidemiology of status epilepticus. J Clin Neurophysiol 1995, 12:316-325.
21. DeLorenzo R.J., Hauser W.A., Towne A.R., et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996, 46:1029-1035.
22. Doty P., Rudd G.D., Stoehr T., et al. Lacosamide. Neurotherapeutics 2007, 4:145-148.
23. Dreifuss F.E., Rosman N.P., Cloyd J.C., et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med 1998, 338:1869-1875.
24. Fountain N.B. Status epilepticus: risk factors and complications. Epilepsia 2000, 41:S23-S30.
25. Fujita H., Muranaka H., Maruyama H. Intranasal midazolam for prevention of status epilepticus. No To Hattatsu 2001, 33:283-284.
26. Gallentine W.B., Hunnicutt A.S., Husain A.M. Levetiracetam in children with refractory status epilepticus. Epilepsy Behav 2009, 14:215-218.
27. Garzon E., Fernandes R.M., Sakamoto A.C. Analysis of clinical characteristics and risk factors for mortality in human status epilepticus. Seizure 2003, 12:337-345.
28. Gastaut H. Clinical and electroencephalographical classification of epileptic seizures. Epilepsia 1970, 11:102-113.
29. Gastaut H. Classification of status epilepticus. Adv Neurol 1983, 34:15-35.
30. Gibbs J.E., Walker M.C., Cock H.R. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 2006, 47:469-478.
31. Gilad R., Izkovitz N., Dabby R., et al. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand 2008, 118:296-300.
32. Gilat E., Goldman M., Lahat E., et al. Nasal midazolam as a novel anticonvulsive treatment against organophosphate-induced seizure activity in the guinea pig. Arch Toxicol 2003, 77:167-172.
33. Greenblatt D.J., Divoll M. Diazepam versus lorazepam: relationship of drug distribution to duration of clinical action. Adv Neurol 1983, 34:487-491.
34. Grosse P., Rusch L., Schmitz B. Pancreatitis complicating treatment with intravenous valproic acid. J Neurol 2002, 249:484-485.
35. Hauser W.A. Status epilepticus: epidemiologic considerations. Neurology 1990, 40:9-13.
36. Hesdorffer D.C., Logroscino G., Cascino G., et al. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology 1998, 50:735-741.
37. Hesdorffer D.C., Logroscino G., Cascino G., et al. Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus. Ann Neurol 1998, 44:908-912.
38. Holtkamp M., Othman J., Buchheim K., et al. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 2005, 76:534-539.
39. Jallon P., Coeytaux A., Galobardes B., et al. Incidence and case-fatality rate of status epilepticus in the Canton of Geneva. Lancet 1999, 353:1496.
40. Jamerson B.D., Dukes G.E., Brouwer K.L., et al. Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy 1994, 14:47-52.
41. Kalviainen R. Status epilepticus treatment guidelines. Epilepsia 2007, 48:99-102.
42. Kaplan P.W. Intravenous valproate treatment of generalized nonconvulsive status epilepticus. Clin Electroencephalogr 1999, 30:1-4.
43. Kaplan P.W. Prognosis in nonconvulsive status epilepticus. Epileptic Disord 2000, 2:185-193.
44. Kellinghaus C., Berning S., Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav 2009, 14:429-431.
45. Kendall J.L., Reynolds M., Goldberg R. Intranasal midazolam in patients with status epilepticus. Ann Emerg Med 1997, 29:415-417.
46. Kilarski D.J., Buchanan C., Von Behren L. Soft-tissue damage associated with intravenous phenytoin. N Engl J Med 1984, 311:1186-1187.
47. Knake S., Rosenow F., Vescovi M., et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia 2001, 42:714-718.
48. Knake S., Rochon J., Fleischer S., et al. Status epilepticus after stroke is associated with increased long-term case fatality. Epilepsia 2006, 47:2020-2026.
49. Knake S., Gruener J., Hattemer K., et al. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry 2008, 79:588-589.
50. Knoester P.D., Jonker D.M., Van Der Hoeven R.T., et al. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol 2002, 53:501-507.
51. Krauss G., Ben-Menachem E., Mameniskiene R., SP757 Study Group, et al. Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures. Epilepsia 2010, 51:951-957.
52. Kyrkou M., Harbord M., Kyrkou N., et al. Community use of intranasal midazolam for managing prolonged seizures. J Intellect Dev Disabil 2006, 31:131-138.
53. Leppik I.E., Derivan A.T., Homan R.W., et al. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983, 249:1452-1454.
54. Logroscino G., Hesdorffer D.C., Cascino G., et al. Mortality after a first episode of status epilepticus in the United States and Europe. Epilepsia 2005, 46:46-48.
55. Lowenstein D.H., Alldredge B.K. Status epilepticus at an urban public hospital in the 1980s. Neurology 1993, 43:483-488.
56. Lowenstein D.H., Alldredge B.K. Status epilepticus. N Engl J Med 1998, 338:970-976.
57. Mahmoudian T., Zadeh M.M. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav 2004, 5:253-255.
58. Mayer S.A., Claassen J., Lokin J., et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002, 59:205-210.
59. Mazarati A.M., Baldwin R., Klitgaard H., et al. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res 2004, 58:167-174.
60. Mehta V., Singhi P., Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. J Child Neurol 2007, 22:1191-1197.
61. Meierkord H. The risk of epilepsy after status epilepticus in children and adults. Epilepsia 2007, 48:94-95.
62. Meierkord H., Boon P., Engelsen B., et al. EFNS guideline on the management of status epilepticus. Eur J Neurol 2006, 13:445-450.
63. Meierkord H., Boon P., Engelsen B., et al. European Federation of Neurological Societies. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 2010, 17:348-355.
64. Minicucci F., Muscas G., Perucca E., et al. Treatment of status epilepticus in adults: guidelines of the Italian League against Epilepsy. Epilepsia 2006, 47:9-15.
65. Misra U.K., Kalita J., Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 2006, 67:340-342.
66. Möddel G., Bunten S., Dobis C., et al. Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus. J Neurol Neurosurg Psychiatry 2009, 80:689-692.
67. Olsen K.B., Tauboll E., Gjerstad L. Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults. Acta Neurol Scand Suppl 2007, 187:51-54.
68. Peters C.N., Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus: experience in 102 adult patients. Seizure 2005, 14:164-169.
69. Prasad K., Al Roomi K., Krishnan P.R., et al. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev 2005, CD003723.
70. Ramael S., Daoust A., Otoul C., et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 2006, 47:1128-1135.
71. Ramael S., De Smedt F., Toublanc N., et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther 2006, 28:734-744.
72. Rao V.K., Feldman P.D., Dibbell D.G. Extravasation injury to the hand by intravenous phenytoin. Report of three cases. J Neurosurg 1988, 68:967-969.
73. Rosenow F., Arzimanoglou A., Baulac M. Recent developments in treatment of status epilepticus: a review. Epileptic Disord 2002, 4:S41-S51.
74. Rossetti A.O. Which anesthetic should be used in the treatment of refractory status epilepticus?. Epilepsia 2007, 48:52-55.
75. Rossetti A.O., Logroscino G., Bromfield E.B. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 2005, 62:1698-1702.
76. Rüegg S., Naegelin Y., Hardmeier M., et al. Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav 2008, 12:477-480.
77. Sheth R.D., Gidal B.E. Refractory status epilepticus: response to ketamine. Neurology 1998, 51:1765-1766.
78. Spengler R.F., Arrowsmith J.B., Kilarski D.J., et al. Severe soft-tissue injury following intravenous infusion of phenytoin. Patient and drug administration risk factors. Arch Intern Med 1988, 148:1329-1333.
79. Stohr T., Kupferberg H.J., Stables J.P., et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 2007, 74:147-154.
80. Tomson T. Mortality in epilepsy. J Neurol 2000, 247:15-21.
81. Towne A.R., Pellock J.M., Ko D., et al. Determinants of mortality in status epilepticus. Epilepsia 1994, 35:27-34.
82. Towne A.R., Waterhouse E.J., Boggs J.G., et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology 2000, 54:340-345.
83. Treiman D.M., Meyers P.D., Walton N.Y., et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998, 339:792-798.
84. Trinka E. The use of valproate and new antiepileptic drugs in status epilepticus. Epilepsia 2007, 48:49-51.
85. Trinka E., Dobesberger J. New treatment options in status epilepticus: a critical review on intravenous levetiracetam. Ther Adv Neurol Dis 2009, 2:79-91.
86. Uberall M.A., Trollmann R., Wunsiedler U., et al. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology 2000, 54:2188-2189.
87. Uges J.W., van Huizen M.D., Engelsman J., et al. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. Epilepsia 2009, 50:415-421.
88. Uusimaa J., Hinttala R., Rantala H., et al. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. Epilepsia 2008, 49:1038-1045.
89. Velioglu S.K., Gazioglu S. Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy. Acta Neurol Scand 2007, 116:128-132.
90. Vignatelli L., Tonon C., D'Alessandro R. Incidence and short-term prognosis of status epilepticus in adults in Bologna, Italy. Epilepsia 2003, 44:964-968.
91. Vignatelli L., Rinaldi R., Galeotti M., et al. Epidemiology of status epilepticus in a rural area of northern Italy: a 2-year population-based study. Eur J Neurol 2005, 12:897-902.
92. Wallace S.J. Nasal benzodiazepines for management of acute childhood seizures?. Lancet 1997, 349:222.
93. Waterhouse E.J., Vaughan J.K., Barnes T.Y., et al. Synergistic effect of status epilepticus and ischemic brain injury on mortality. Epilepsy Res 1998, 29:175-183.
94. Wermeling D.P. Intranasal delivery of antiepileptic medications for treatment of seizures. Neurotherapeutics 2009, 6:352-358.
95. Wheless J.W., Vazquez B.R., Kanner A.M., et al. Rapid infusion with valproate sodium is well tolerated in patients with epilepsy. Neurology 2004, 63:1507-1508.
96. Wolfe T.R., Macfarlane T.C. Intranasal midazolam therapy for pediatric status epilepticus. Am J Emerg Med 2006, 24:343-346.
97. Wu Y.W., Shek D.W., Garcia P.A., et al. Incidence and mortality of generalized convulsive status epilepticus in California. Neurology 2002, 58:1070-1076.
98. Yaffe K., Lowenstein D.H. Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus. Neurology 1993, 43:895-900.
99. Yu K.T., Mills S., Thompson N., et al. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia 2003, 44:724-726.